The Efficacy of Tasquinimod in Men with mCRPC

March 28, 2014
Roberto Pili, MD

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer (CRPC).

Clinical Pearls:

  • Tasquinimod has a multifocal effect on the microenvironment of the tumor
  • This drug is still in clinical development, but has shown significant activity in patients with metastatic prostate cancer
  • In a phase II study, patients who were randomized to tasquinimod had double the progression-free survival compared to those in the placebo arm